Investigation of effects of sigma 1 agonist fluvoxamine on tardive dyskinesia symptoms in rats

Tardive dyskinesia is involuntary complex movements that occur with long-term antipsychotic treatment, often whose symptoms are overshadowed by treatment, but become clear after treatment is reduced or terminated. The aim of this study was to establish a tardive dyskinesia model in rats by chronic administration of haloperidol to rats; to test whether fluvoxamine can be an alternative treatment by comparing the fluvoxamine treated rat group with the control group, haloperidol group and haloperidol+tetrabenazine group in terms of biochemical and behavioral parameters. For this purpose, 32 Wistar Albino male rats were divided into 4 groups as control group, haloperidol group, haloperidol+fluvoxamine group and haloperidol+tetrabenazine group. Behavioral observations of the rats were carried out by open field test and elevated maze test, then samples were taken from the hippocampus, striatum region and frontal lobe tissues and BDNF, NGF, SOD and MDA levels were measured. Significant differences were determined between the groups in terms of behavioral observations. SOD level in the hippocampus; BDNF, NGF and SOD levels in the striatum of the haloperidol+fluvoxamine group were found to be significantly higher than in the haloperidol group, while MDA levels in the hippocampus were found to be significantly lower than in the haloperidol group. In addition, it was determined that there were significant differences between the haloperidol+tetrabenazine group and the other groups in terms of biochemical parameters. It is thought that the results will contribute to the understanding of the complex biological mechanism and the treatment of tardive dyskinesia by revealing positive biochemical changes on brain growth factors and oxidative stress factors through the sigma 1 agonism of fluvoxamine. Keywords: Tardive dyskinesia, fluvoxamine, brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), superoxide dismutase (SOD), malondialdehyde (MDA) Keywords: Tardive dyskinesia, fluvoxamine, brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), superoxide dismutase (SOD), malondialdehyde (MDA)